Integrin subunit beta 8 contributes to lenvatinib resistance in HCC
Abstract Lenvatinib is a multikinase inhibitor approved as a first‐line therapy for advanced hepatocellular carcinoma (HCC). However, the development of drug resistance is common, and the underlying mechanisms governing this resistance are largely unknown. In this study, we established two lenvatini...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health/LWW
2022-07-01
|
| Series: | Hepatology Communications |
| Online Access: | https://doi.org/10.1002/hep4.1928 |